stockrowCG Oncology, Inc. (CGON) vs Ligand Pharmaceuticals Incorporated (LGND)
- CG Oncology, Inc. CGON 76.08 +17.41%
- Ligand Pharmaceuticals Incorporated LGND 306.43 +2.48%
CG Oncology, Inc. and Ligand Pharmaceuticals Incorporated are both Biotechnology companies. CG Oncology, Inc. and Ligand Pharmaceuticals Incorporated are of similar size ($6.0B and $5.7B). CG Oncology, Inc. has negative trailing earnings, so its P/E is not meaningful; Ligand Pharmaceuticals Incorporated trades at 116×. CG Oncology, Inc. grew revenue faster over the last twelve months: 840.8% against 1.03%. Ligand Pharmaceuticals Incorporated has the higher net margin (20.3% vs −3,602.7%) and the higher return on invested capital (1.27% vs −4,111.6%). Across the 17 metrics below, Ligand Pharmaceuticals Incorporated leads on 13 and CG Oncology, Inc. on 4.
Valuation
Profitability
| Metric | CGON | LGND | Biotechnology median |
|---|---|---|---|
| Gross margin | (85.20%) | 95.22% | 65.16% |
| Operating margin | (4,056.18%) | 9.29% | 0.00% |
| Net margin | (3,602.68%) | 20.27% | 0.00% |
| Free cash flow margin | (2,879.62%) | 31.43% | 0.00% |
| Return on equity | (26.41%) | 5.38% | (50.12%) |
| Return on assets | (25.11%) | 2.77% | (45.60%) |
| Return on invested capital | (4,111.64%) | 1.27% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack